RU2008142600A - Органическое соединение - Google Patents
Органическое соединение Download PDFInfo
- Publication number
- RU2008142600A RU2008142600A RU2008142600/04A RU2008142600A RU2008142600A RU 2008142600 A RU2008142600 A RU 2008142600A RU 2008142600/04 A RU2008142600/04 A RU 2008142600/04A RU 2008142600 A RU2008142600 A RU 2008142600A RU 2008142600 A RU2008142600 A RU 2008142600A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- alkylamino
- represents hydrogen
- halogen
- aryl
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 103
- 239000001257 hydrogen Substances 0.000 claims abstract 103
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims abstract 81
- 229910052736 halogen Chemical group 0.000 claims abstract 55
- 150000002367 halogens Chemical group 0.000 claims abstract 54
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 49
- 230000003287 optical effect Effects 0.000 claims abstract 26
- 150000003573 thiols Chemical group 0.000 claims abstract 25
- 150000001875 compounds Chemical class 0.000 claims abstract 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 14
- 239000000203 mixture Substances 0.000 claims abstract 13
- 150000003839 salts Chemical class 0.000 claims abstract 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 12
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 12
- 239000001301 oxygen Substances 0.000 claims abstract 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 9
- 229910052799 carbon Inorganic materials 0.000 claims abstract 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 59
- 125000003118 aryl group Chemical group 0.000 claims 52
- 125000001072 heteroaryl group Chemical group 0.000 claims 39
- 150000002431 hydrogen Chemical class 0.000 claims 38
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 29
- 125000003545 alkoxy group Chemical group 0.000 claims 27
- 125000000623 heterocyclic group Chemical group 0.000 claims 27
- 125000001424 substituent group Chemical group 0.000 claims 26
- 125000003342 alkenyl group Chemical group 0.000 claims 25
- -1 cyano, carboxy Chemical group 0.000 claims 24
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 22
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 21
- 125000000304 alkynyl group Chemical group 0.000 claims 21
- 125000004442 acylamino group Chemical group 0.000 claims 19
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 19
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 125000004432 carbon atom Chemical group C* 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 claims 8
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000000883 anti-obesity agent Substances 0.000 claims 2
- 239000002220 antihypertensive agent Substances 0.000 claims 2
- 229940030600 antihypertensive agent Drugs 0.000 claims 2
- 239000003524 antilipemic agent Substances 0.000 claims 2
- 229940125710 antiobesity agent Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000004041 inotropic agent Substances 0.000 claims 2
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 208000019025 Hypokalemia Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 125000004986 diarylamino group Chemical group 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000024896 potassium deficiency disease Diseases 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 16
- 150000001721 carbon Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78710406P | 2006-03-29 | 2006-03-29 | |
| US60/787,104 | 2006-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008142600A true RU2008142600A (ru) | 2010-05-10 |
Family
ID=38477291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008142600/04A RU2008142600A (ru) | 2006-03-29 | 2007-03-27 | Органическое соединение |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8153674B2 (https=) |
| EP (2) | EP2001866A2 (https=) |
| JP (1) | JP5197569B2 (https=) |
| KR (1) | KR20080114769A (https=) |
| CN (1) | CN101410389A (https=) |
| AU (1) | AU2007234968A1 (https=) |
| BR (1) | BRPI0709678A2 (https=) |
| CA (1) | CA2644391A1 (https=) |
| ES (1) | ES2442347T3 (https=) |
| MX (1) | MX2008012402A (https=) |
| RU (1) | RU2008142600A (https=) |
| WO (1) | WO2007117982A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ552397A (en) | 2004-07-15 | 2011-04-29 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| KR20090090395A (ko) * | 2006-12-18 | 2009-08-25 | 노파르티스 아게 | 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도 |
| EA200900811A1 (ru) * | 2006-12-18 | 2009-12-30 | Новартис Аг | Имидазолы в качестве ингибиторов альдостеронсинтазы |
| EP2095819A1 (en) | 2008-02-28 | 2009-09-02 | Maastricht University | N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| AU2010247763B2 (en) | 2009-05-12 | 2015-12-24 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
| WO2010132437A1 (en) | 2009-05-12 | 2010-11-18 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| AU2010247735B2 (en) | 2009-05-12 | 2015-07-16 | Albany Molecular Research, Inc. | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof |
| AR088989A1 (es) * | 2011-11-30 | 2014-07-23 | Hoffmann La Roche | Derivados biciclicos de dihidroisoquinolin-1-ona |
| CN103958478B (zh) * | 2011-11-30 | 2017-08-01 | 霍夫曼-拉罗奇有限公司 | 双环二氢异喹啉‑1‑酮衍生物 |
| EP2639212B1 (en) | 2012-03-13 | 2016-03-09 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Enantioselective organic anhydride reactions |
| HUE039981T2 (hu) * | 2014-07-24 | 2019-02-28 | Boehringer Ingelheim Int | Aldoszteron szintáz inhibitorok |
| WO2016123275A1 (en) * | 2015-01-30 | 2016-08-04 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| WO2018165649A1 (en) | 2017-03-10 | 2018-09-13 | Embera Neurotherapeutics, Inc. | Pharmaceutical compositions and uses thereof |
| CN109232607A (zh) * | 2018-09-20 | 2019-01-18 | 沈阳药科大学 | 劳拉替尼的合成方法 |
| EP3962903A1 (en) | 2019-05-01 | 2022-03-09 | Boehringer Ingelheim International GmbH | (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate |
| TW202339719A (zh) | 2021-12-14 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療慢性腎臟病之醛固酮合成酶抑制劑 |
| WO2024109885A1 (zh) * | 2022-11-23 | 2024-05-30 | 上海翰森生物医药科技有限公司 | 吡啶多环类化合物抑制剂、及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4904300A (en) * | 1987-08-26 | 1990-02-27 | Ciba-Geigy Corp. | Imidazole derivatives |
| DE102004035322A1 (de) * | 2004-07-21 | 2006-02-16 | Universität des Saarlandes | Selektive Hemmstoffe humaner Corticoidsynthasen |
-
2007
- 2007-03-27 EP EP07759422A patent/EP2001866A2/en not_active Withdrawn
- 2007-03-27 WO PCT/US2007/064974 patent/WO2007117982A2/en not_active Ceased
- 2007-03-27 ES ES10179603.5T patent/ES2442347T3/es active Active
- 2007-03-27 KR KR1020087023643A patent/KR20080114769A/ko not_active Withdrawn
- 2007-03-27 MX MX2008012402A patent/MX2008012402A/es not_active Application Discontinuation
- 2007-03-27 BR BRPI0709678-0A patent/BRPI0709678A2/pt not_active Application Discontinuation
- 2007-03-27 JP JP2009503206A patent/JP5197569B2/ja not_active Expired - Fee Related
- 2007-03-27 US US12/295,155 patent/US8153674B2/en not_active Expired - Fee Related
- 2007-03-27 EP EP10179603.5A patent/EP2301931B1/en not_active Not-in-force
- 2007-03-27 CN CNA2007800110014A patent/CN101410389A/zh active Pending
- 2007-03-27 CA CA002644391A patent/CA2644391A1/en not_active Abandoned
- 2007-03-27 AU AU2007234968A patent/AU2007234968A1/en not_active Abandoned
- 2007-03-27 RU RU2008142600/04A patent/RU2008142600A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007117982A2 (en) | 2007-10-18 |
| EP2301931B1 (en) | 2013-10-16 |
| CA2644391A1 (en) | 2007-10-18 |
| US8153674B2 (en) | 2012-04-10 |
| ES2442347T3 (es) | 2014-02-11 |
| EP2001866A2 (en) | 2008-12-17 |
| AU2007234968A1 (en) | 2007-10-18 |
| US20090182007A1 (en) | 2009-07-16 |
| JP2009531457A (ja) | 2009-09-03 |
| JP5197569B2 (ja) | 2013-05-15 |
| WO2007117982A3 (en) | 2007-12-13 |
| CN101410389A (zh) | 2009-04-15 |
| MX2008012402A (es) | 2008-10-09 |
| BRPI0709678A2 (pt) | 2011-07-19 |
| KR20080114769A (ko) | 2008-12-31 |
| EP2301931A1 (en) | 2011-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008142600A (ru) | Органическое соединение | |
| RU2009110442A (ru) | Конденсированные производные имидазола для лечения нарушений, опосредованных альдостеронсинтазой, и/или 11-бета-гидроксилазой, и/или ароматазой | |
| EA200971115A1 (ru) | Новые ингибиторы обратной транскриптазы вич | |
| NO20090835L (no) | Nye HIV-reverstranskriptaseinhibitorer | |
| EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| PE20242219A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
| EA200700099A1 (ru) | Производные пиридина | |
| AR062409A1 (es) | Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto | |
| CY1106679T1 (el) | Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα | |
| AR084768A1 (es) | Moduladores de la senda de complemento y usos de los mismos | |
| CO6470846A2 (es) | Derivados aminobut´ricos sustituidos como inhibidores de neprilisina | |
| CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| DE60320012D1 (de) | Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen | |
| RU2009127642A (ru) | 1-замещенные производные имидазола и их применение в качестве ингибиторов альдостеронсинтазы | |
| EA201171333A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias | |
| BRPI0707491B8 (pt) | compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas | |
| EA202090658A1 (ru) | Ингибиторы кэп-зависимой эндонуклеазы | |
| EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
| RU2011106356A (ru) | Модуляторы рецептора сфингозин-1-фосфата (s1p) и их применение для лечения воспаления мышечной ткани | |
| AR043658A1 (es) | Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona | |
| AR063577A1 (es) | Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos | |
| AR053092A1 (es) | Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis | |
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| JP2017500321A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110214 |